NCT06549907View on ClinicalTrials.gov

A Biomarker Exploratory Study of Dual Blockade of PD1/PDL1 and CTLA4 and Anti-angiogenic Therapy

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

January 10, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2028

Conditions
MSS Metastatic Colorectal CancersMSI Solid Tumors Refractory to PD1/PDL1 Antibody Monotherapy
Interventions
OTHER

Multi-omics testing

Samples include tissue, blood, urine and stool, and multi-omics approaches include single-cell sequencing, spatial transcriptome sequencing, macro transcriptome sequencing, whole exome sequencing, microproteomics, immunohistochemistry, and multiplex fluorescence immunohistochemistry.

OTHER

MRI

MRI will be conducted to investigate image characteristics during treatment

Trial Locations (1)

100142

RECRUITING

Jian Li, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER